The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies

New England Journal of Medicine

Volumn 335, Issue 13, 1996, Pages 924-930

  Hsich, Gary ^a   Kenney, Kimbra ^a   Gibbs Jr , Clarence J ^a,c   Lee, Kelvin H ^b   Harrington, Michael G ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^c Division of Intramural Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; MARKER;

AMINO ACID SEQUENCE; ARTICLE; BRAIN SPONGIOSIS; CONTROLLED STUDY; COW; CREUTZFELDT JAKOB DISEASE; DEMENTIA; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; TWO DIMENSIONAL ELECTROPHORESIS; VIRUS ENCEPHALITIS;

14-3-3 PROTEINS; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID PROTEINS; CREUTZFELDT-JAKOB SYNDROME; DEMENTIA; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOASSAY; MOLECULAR SEQUENCE DATA; PRION DISEASES; PROTEINS; SENSITIVITY AND SPECIFICITY; TYROSINE 3-MONOOXYGENASE;

EID: 0029840653     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199609263351303     Document Type: Article

References (37)

1. Brown P. Transmissible human spongiform encephalopathy (infectious cerebral amyloidosis): Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, and kuru. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: W.B. Saunders, 1994:839-76.
2. Medori R, Tritschler H-J, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 1992;326:444-9.
3. Gajdusek DC. Infectious amyloids: subacute spongiform encephalopathies as transmissible cerebral amyloidosis. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed. Vol. 2. Philadelphia: Lippincott-Raven, 1996:2851-900.
4. Prusiner SB. Prions. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed. Vol. 2. Philadelphia: Lippincott-Raven, 1996:2901-50.
5. Brown P, Preece MA, Will RG. "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992;340:24-7.
6. Asher DM, Gibbs CJ, Gajdusek DC. Slow viral infections: safe handling of the agents of subacute spongiform encephalopathies. In: Miller BM, ed. Laboratory safety: principles and practices. Washington, D.C.: American Society for Microbiology, 1986:59-71.
7. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-5.
8. Jimi T, Wakayama Y, Shibuya S, et al. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 1992;211:37-46.
9. Zerr I, Bodemer M, Räcker S, et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 1995;345:1609-10.
10. Manaka H, Kato T, Kurita K, et al. Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt Jakob disease. Neurosci Lett 1992;139:47-9.
11. Awerbuch G, Peterson P, Sandyk R. Elevated cerebrospinal fluid lactic acid levels in Creutzfeldt-Jakob disease. Int J Neurosci 1988;42:1-5.
12. Harrington MG, Merril CR, Asher DM, Gajdusek DC. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N Engl J Med 1986;315:279-83.
13. Croxson M, Brown P, Synek B, et al. A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand. Neurology 1988;38:1128-30.
14. Blisard KS, Davis LE, Harrington MG, Lovell JK, Kornfeld M, Berger ML. Pre-mortem diagnosis of Creutzfeldt-Jakob disease by detection of abnormal cerebrospinal fluid proteins. J Neurol Sci 1990;99:75-81.
15. Marzewski DJ, Towfighi J, Harrington MG, Merril CR, Brown P. Creutzfeldt-Jakob disease following pituitary-derived human growth hormone therapy: a new American case. Neurology 1988;38:1131-3.
16. Macario ME, Vaisman M, Buescu A, Neto VM, Araujo HM, Chagas C. Pituitary growth hormone and Creutzfeldt-Jakob disease. BMJ 1991; 302:1149.
17. Brown P, Cathala F, Castaigne P, Gajdusek DC. Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 1986;20:597-602.
18. Bjellqvist B, Sanchez JC, Pasqnali C, et al. Micropreparative two dimensional electrophoresis allowing the separation of samples containing milligram amounts of proteins. Electrophoresis 1993;14:1375-8.
19. Bjellqvist B, Pasquali C, Ravier F, Sanchez JC, Hochstrasser D. A non-linear wide-range immobilized pH gradient for two-dimensional electro phoresis and its definition in a relevant pH scale. Electrophoresis 1993;14: 1357-65.
20. Harrington MG, Gudeman D, Zewert T, Yun M, Hood L. Analytical and micropreparative two-dimensional electrophoresis of proteins. Meth ods Companion Methods Enzymol 1991;3:98-108.
21. Solomon JE, Harrington MG. A robust, high-sensitivity algorithm tor automated detection of proteins in two-dimensional electrophoresis gels. Comput Appl Biosci 1993;9:133-9.
22. Towbin H, Stachelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
23. Acbersold RH, Pipes G, Hood LE, Kent SBH. N-terminal and internal sequence determination of microgram amounts of proteins separated by isoelectric focusing in immobilized pH gradients. Electrophoresis 1988; 9:520-30.
24. Brown P, Coker-Vann M, Pomeroy K, et al. Diagnosis of Creutzfeldt-Jakob disease by Western blot identification of marker protein in human brain tissue. N Engl J Med 1986;314:547-51.
25. Rosner B. Fundamentals of biostatistics. 2nd ed. Boston: Duxbury Press, 1986.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-44.
27. Boston PF, Jackson P, Kynoch PAM, Thompson RJ. Purification, properties, and immunohistochemical localisation of human brain 14-3-3 protein. J Neurochem 1982;38:1466-74.
28. Aitken A, Collinge DB, van Heusden BPH, et al. 14-3-3 Proteins: a highly conserved, widespread family of cukaryotic proteins. Trends Biochem Sci 1992;17:498-501.
29. Burbelo PD, Hall A. 14-3-3 Proteins: hot numbers in signal transduction. Curr Biol 1995;5:95-6.
30. Robinson K, Jones D, Patel Y, et al. Mechanism of inhibition of protein kinase C by 14-3-3 isoforms: 14-3-3 isoforms do not have phospholipase A2 activity. Biochem J 1994;299:853-61.
31. Ichimura T, Isobe T, Okuyama T, et al. Molecular cloning of cDNA coding tor brain-specific 1433 protein, a protein-kinase dependent activator of tyrosine and tryptophan hydroxylases. Proc Natl Acad Sci U S A 1988;85:7084-8.
32. Morgan A, Burgoyne RD. Exo1 and Exo2 proteins stimulate calcium-dependent exocytosis in permeabilized adrenal chromaffin cells. Nature 1992;355:833-6.
33. Freed E, Symons M, Macdonald SG, McCormick F, Ruggieri R. Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 1994;265:1713-6.
34. Fantl WJ, Muslin AJ, Kikuchi A, et al. Activation of Raf-1 by 14-3-3 proteins. Nature 1994,371:612-4.
35. Irie K, Gotoh Y, Yashar BM, Errede B, Nishida E, Matsumoto K. Stimulatory effects of yeast and mammalian 14-3-3 proteins on the Raf protein kinase. Science 1994;265:1716-9.
36. Morrison D. 14-3-3: Modulators of signaling proteins? Science 1994; 266:56-7
37. Boston PF, Jackson P, Thompson RJ. Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J Neurochem 1982;38:1475-82.